Who is a Class Member
- Class Members of the Menactra Meningitis Vaccine Antitrust settlement include “all persons and entities in the United States and its territories that purchased Menactra directly from Sanofi Pasteur (or any of its affiliates, divisions, predecessors or subsidiaries, such as VaxServe Inc.) at any time from March 1, 2010 through Dec. 31, 2014.”
If you don’t qualify for this settlement, check out our database of otheryou may be eligible for.
Settlement payouts will be based on a number of factors, including:
- the total number of valid claims filed
- the total dollar value of all filed claims
- the total money available to pay all claims
It is estimated there are roughly 30,000 eligible class members.
Proof of Purchase
- If you do not agree with the sales transaction data in Part 2 of your Claim Form, you will need to submit valid documentation to support the purchase you claim. Acceptable documentation includes copies of:
- purchase invoices
- internal purchase records or ledgers certified by your purchasing (accounts payable) department or an independent accountant and must include:
- date of purchase
- purchased product was Menactra
- purchaser (including proof that the purchaser is you, your related company or your valid assignor and the purchaser was invoiced by Sanofi for the purchase and appears as “bill to” or “sold to” entity in the transactional data)
- the amount of doses purchased
Menactra Meningitis Vaccine Antitrust Settlement Notes
- Adriana M. Casto, et al. v. Sanofi Pasteur Inc.
- Case No. 2:11-cv-07178-JMV-MAH
- Pending in the U.S. District Court for District of New Jersey
In January 2012, three pediatric physician practices challenged an alleged anticompetitive scheme by Sanofi Pasteur to limit its competition in the U.S. market for meningococcal vaccines, claiming violations of U.S. antitrust laws. Specifically, the Menactra meningitis vaccine antitrust class action lawsuit claims that Sanofi used its market power to impose bundling-pricing contracts forcing physicians, medical practices, vaccine distributors/wholesalers, and health systems who bought Menactra directly from Sanofi to pay higher prices than they should have for quadrivalent meningococcal vaccines (MCV4 vaccines).
Sanofi asserts that its conduct, including its discounting practices, benefits purchasers of MCV4 Vaccines (and consumers more generally) and that it did not engage in any illegal conduct, that its actions did not raise prices to noncompetitive levels, and that any alleged anticompetitive effects from its conduct are outweighed by the conduct’s pro-competitive effects. Sanofi also denies that Novartis’s entry was foreclosed and that it and Novartis would each have lowered vaccines prices if not for the conduct alleged in this lawsuit.
The court granted final approval to the Menactra class action settlement on October 20, 2017. Class members who wish to submit a claim must do so by Jan. 18, 2018.
- 1/18/18: Claim Form Deadline
Note: On Oct. 20, 2017 the court granted final approval to the Menactra class action settlement. Claims will be dispersed after the claim deadline, which is Jan. 18, 2018. Be sure to let Class Action Wallet know when you receive your piece of the settlement pie in the comments below!
- Mail: Menactra Antitrust Litigation Settlement, c/o Rust Consulting Inc,-5203, PO Box 2563, Faribault, MN 55021-9563
- Phone: 1-866-216-0279